Elevance Health is stepping up its focus on AI-driven efficiency and mental health. The increase in its 2026 earnings outlook and progress in AI adoption are drawing market attention.
In its report for the second quarter of 2026, Elevance Health raised its full-year diluted earnings per share (EPS) guidance to at least $20.10. The report also included comments that the use of AI tools has reduced the number of prior authorization denials and improved payment integrity.
According to the company’s analysis, revenue through 2029 is expected to reach approximately $209.8 billion, with profit of approximately $7.3 billion. Achieving this would require annual revenue growth of approximately 1.4% and an increase in current profit of $5 billion to approximately $2.3 billion.
The estimated fair value is $449.10, suggesting approximately 13% upside from the current share price.
Under an optimistic scenario, revenue could expand to approximately $214.8 billion and profit to approximately $7.3 billion, although medical cost inflation and policy uncertainty are also viewed as remaining risk factors.